OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.
On June 30, 2022, Inceptor Bio, a US-based biotechnology company specializing in cell therapies for difficult-to-treat cancers, announced a collaboration with the University of Minnesota. Under the collaboration, the two parties plan to build a novel induced pluripotent stem cells (iPSC) platform to accelerate Inceptor Bio’s next-generation cell therapies platforms.
Inceptor Bio will receive an exclusive license to the technology developed under this collaboration. The company plans to advance multiple cell therapy products into clinical studies by incorporating the iPSC platform into its proprietary K62 platform for chimeric antigen receptor macrophage (CAR-M) therapy. CAR-M therapy increases the phagocytic capabilities of macrophages and supports a macrophage 1 (M1) anti-tumor phenotype as well as its novel co-stimulatory domain, M83, for CAR-natural killer cell therapies.
"iPSC-derived cell therapies have the potential to enable the next frontier of cell therapies. We are excited to work with [Beau] Webber at University of Minnesota and his team to develop this unique platform," said Mike Nicholson, president and chief operating officer, Inceptor Bio, in a company press release.
"The team at University of Minnesota is confident that Inceptor Bio is the right partner for building a differentiated iPSC platform to advance novel cell therapies," said Beau Webber, assistant professor in the Department of Pediatrics, Division of Hematology and Oncology, University of Minnesota, in the press release. "We are deeply encouraged by Inceptor Bio’s progress in the cell therapy arena, and we look forward to being part of future developments to help cure difficult-to-treat cancers."
Source: Inceptor Bio